Cargando…

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters

The radio-iodinated noradrenaline analogue meta-iodobenzylguanidine (MIBG) can be used for scintigraphy and radiation therapy of neuroendocrine (NE). The aim of the present study was to study the importance of vesicular monoamine transporters (VMATs) for the uptake of (123)I-MIBG in NE tumours. In n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kölby, L, Bernhardt, P, Levin-Jakobsen, A-M, Johanson, V, Wängberg, B, Ahlman, H, Forssell-Aronsson, E, Nilsson, O
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394326/ https://www.ncbi.nlm.nih.gov/pubmed/14520475 http://dx.doi.org/10.1038/sj.bjc.6601276

Ejemplares similares

Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour
por: Kölby, L, et al.
Publicado: (2005)

Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
por: Wangberg, B., et al.
Publicado: (1996)

Somatostatin receptors on neuroendocrine tumors--a way to intraoperative diagnosis and localization.
por: Ahlman, H., et al.
Publicado: (1994)

Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin
por: Johanson, V, et al.
Publicado: (1999)

A new method to estimate parameters of the growth model for metastatic tumours
por: Mehrara, Esmaeil, et al.
Publicado: (2013)

The relevance of somatostatin receptors in thyroid neoplasia.
por: Ahlman, H., et al.
Publicado: (1997)

Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid
por: Tisell, L E, et al.
Publicado: (1999)

Estimation of absorbed dose to the kidneys in patients after treatment with (177)Lu-octreotate: comparison between methods based on planar scintigraphy
por: Larsson, Maria, et al.
Publicado: (2012)

The ins and outs of vesicular monoamine transporters
por: Yaffe, Dana, et al.
Publicado: (2018)

Objective assessment of tumour response to therapy based on tumour growth kinetics
por: Mehrara, E, et al.
Publicado: (2011)

Objective assessment of tumour response to therapy based on tumour growth kinetics
por: Mehrara, E, et al.
Publicado: (2011)

Histamine metabolism of gastric carcinoids in Mastomys natalensis.
por: Kölby, L., et al.
Publicado: (1998)

(177)Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
por: Hofving, Tobias, et al.
Publicado: (2019)

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease
por: Brighina, Laura, et al.
Publicado: (2013)

Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
por: Caroff, Stanley N.
Publicado: (2020)

Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.
por: Armour, A., et al.
Publicado: (1994)

Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management
por: Sreeram, Venkatesh, et al.
Publicado: (2019)

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions
por: Alwindi, Malik, et al.
Publicado: (2023)

NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids
por: Jakobsen, A-M, et al.
Publicado: (2003)

Renal function affects absorbed dose to the kidneys and haematological toxicity during (177)Lu-DOTATATE treatment
por: Svensson, Johanna, et al.
Publicado: (2015)

The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.
por: Wängberg, B., et al.
Publicado: (1991)

An Acidic Motif Retains Vesicular Monoamine Transporter 2 on Large Dense Core Vesicles
por: Waites, Clarissa L., et al.
Publicado: (2001)

Differential Localization of Vesicular Acetylcholine and Monoamine Transporters in PC12 Cells but Not CHO Cells
por: Liu, Yongjian, et al.
Publicado: (1997)

A Glial Variant of the Vesicular Monoamine Transporter Is Required To Store Histamine in the Drosophila Visual System
por: Romero-Calderón, Rafael, et al.
Publicado: (2008)

Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells
Publicado: (1994)

Functional genetic variants in the vesicular monoamine transporter 1 (VMAT1) modulate emotion processing
por: Lohoff, Falk W., et al.
Publicado: (2013)

Preliminary Evidence of Apathetic-Like Behavior in Aged Vesicular Monoamine Transporter 2 Deficient Mice
por: Baumann, Aron, et al.
Publicado: (2016)

A Brief Review on the Role of Vesicular Monoamine Transporter(2) Inhibitors in Hyperkinetic Movement Disorders
por: NIKKHAH, Ali
Publicado: (2021)

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
por: Quintela-Fandino, M, et al.
Publicado: (2013)

Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas
por: Saisho, Yoshifumi, et al.
Publicado: (2008)

Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population
por: Richards, Misty, et al.
Publicado: (2006)

Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men
por: Yang, Xinglong, et al.
Publicado: (2015)

A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2
por: Huang, Zih-Rou, et al.
Publicado: (2016)

Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism
por: Beauchamp, Leah C., et al.
Publicado: (2020)

Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson
por: Pifl, Christian, et al.
Publicado: (2023)

Priming increases the anti-tumor effect and therapeutic window of (177)Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1
por: Dalmo, Johanna, et al.
Publicado: (2017)

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
por: Nilsson, O., et al.
Publicado: (1998)

O(6)-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
por: Walter, T, et al.
Publicado: (2015)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-γ and meta-iodobenzylguanidine
por: Höpfner, Michael, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_dleuj1c1g54ko4r2p2pvd1estt